COMMUNIQUÉS West-GlobeNewswire

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in China
01/10/2019
LA JOLLA, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), [...]
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/10/2019
CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2019, that were [...]
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30/09/2019
CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in [...]
Genfit: H1 2019 Results and R&D Pipeline Progression
30/09/2019
GENFIT: H1 2019 RESULTS AND R&D PIPELINE PROGRESSION Cash position of €282 million (€207 million at December 31, 2018) USD $155 million gross proceeds from the IPO on the Nasdaq Global Select market Signature of a [...]
GENFIT présente ses résultats financiers et l’avancée de son portefeuille de programmes de R&D au premier semestre 2019
30/09/2019
GENFIT présente ses résultats financiers et l’avancée de son portefeuille de programmes de R&D au premier semestre 2019 Trésorerie de Cloture de 282 M€ (contre 207 M€ au 31 décembre 2018) Levée de fonds d’un montant [...]
NewLink Genetics and Lumos Pharma Enter into Merger Agreement to Form Biopharmaceutical Company Focused on Developing Therapies to Treat Rare Diseases
30/09/2019
-- Combined company to assume the name, Lumos Pharma, Inc. and is expected to be led by Richard J. Hawkins, current CEO of Lumos Pharma -- -- Lumos asset, LUM-201, represents first oral therapeutic candidate for [...]
Geron Announces Fast Track Designation Granted to Imetelstat for Relapsed/Refractory Myelofibrosis
30/09/2019
MENLO PARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to imetelstat for the [...]
AnaptysBio Reports Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-to-Severe Generalized Pustular Psoriasis
30/09/2019
Interim analysis conducted with first two patients to complete 16-week (Day 113) ANB019 monotherapy study Both patients achieved the primary endpoint of disease score improvement at Day 29 and Day 113 without requiring [...]
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30/09/2019
HOUSTON, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today [...]
Aduro Biotech to Present at the 2019 Cantor Global Healthcare Conference
30/09/2019
BERKELEY, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Andrea van Elsas, chief scientific officer of Aduro, is scheduled to present at the 2019 Cantor Global [...]
Ocugen to Present at Three Upcoming Conferences
30/09/2019
MALVERN, Pa., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc. , (NASDAQ: OCGN) a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that [...]
Dynavax to Present at the 2019 Cantor Global Healthcare Conference
30/09/2019
BERKELEY, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), today announced that Ryan Spencer, Senior Vice President, Commercial, and Interim Co-President, will present at the [...]
Predictive Technology Group Reports Fiscal Year 2019 Financial Results
30/09/2019
Revenue increases 162% to $43.5 million with $3.5 million in positive cash flow from operations SALT LAKE CITY, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED) (the Company), a [...]
Celldex Therapeutics to Present at the Cantor Global Healthcare Conference
30/09/2019
HAMPTON, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, and Tibor Keler, PhD, Cofounder, [...]
Inventiva completes a capital increase of € 625,000 subscribed by Sofinnova Partners through Sofinnova Crossover I Fund
30/09/2019
Daix (France), September 30 th , 2019 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal [...]
Inventiva réalise une augmentation de capital de 625.000 euros souscrite par Sofinnova Partners, au travers de son fonds Sofinnova Crossover I Fund
30/09/2019
Daix (France), le 30 septembre 2019 – Inventiva (Euronext : IVA), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de maladies dans [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 août 2019
30/09/2019
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 août 2019 En application de l'article L. 233-8 II du code de commerce et de l'article 222-12-5 du règlement général de l'AMF, les [...]
AB Science today reports its revenues for the first half of 2019 and provides an update on its activities.
30/09/2019
Paris, September 30, 2019, 8pm Net loss of 13M€ in the first half of 2019 Operating loss of -10.6M€, a 25.5% expenses decrease as compared with the first half of 2018 (14.2M€) Cash position of 2.7M€ as of 30 June 2019, [...]
AB Science annonce aujourd’hui ses résultats financiers semestriels au 30 juin 2019 et présente un point sur ses activités
30/09/2019
Paris, 30 septembre 2019, 20h Perte nette de 13M€ au premier semestre 2019 Déficit opérationnel de 10,6 M€, soit une réduction des dépenses de 25,5% par rapport au premier semestre 2018 (14,2M€) Trésorerie de 2,7M€ au [...]

Pages